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Introduction: The CYP2C19*17 allele variant is a gain-of-function polymorphism which 
increases levels of the active metabolite of clopidogrel. 
Objective: *17 is associated with increased bleeding risk during clopidogrel therapy, but it is 
unclear whether alternative P2Y12 inhibitors, prasugrel and ticagrelor, produce better clinical 
outcomes in patients undergoing percutaneous coronary intervention (PCI).  
Methods: A single-center observational study was conducted in 928 PCI patients who received 
CYP2C19 testing and dual anti-platelet therapy (DAPT). Risk of major adverse cardiovascular or 
cerebrovascular events (MACCE) and clinically significant bleeding over 12 months were 
compared across genotype and DAPT groups by proportional hazards regression.  
Results: 584 patients were treated with clopidogrel while 344 patients had alternative therapy. In 
the clopidogrel group, 173 patients were hetero- or homozygous for *17 and 91 patients were 
hetero- or homozygous for a loss of function allele (LOF; *2 or *3). Patients treated with 
clopidogrel were older, more commonly female, and more likely to have hypertension, diabetes, 
and an acute coronary syndrome (ACS) than patients on alternative therapy. There were no 
differences in MACCE or clinically significant bleeding events in *17 patients treated with 
clopidogrel compared to alternative therapy in either the total population (p=0.54) or in ACS 
patients (p=0.98). Patients with LOF alleles were 3.4 times more likely in the total population (p 
<0.0001) and 6.7 times more likely among ACS patients (p <0.0001) to have MACCE if 
prescribed clopidogrel compared with alternative therapy. 
Discussion: *17 patients had equivalent clinical outcomes when treated with clopidogrel or 
alternative P2Y12 inhibitors.  
